Oslo, 19 September 2025: Reference is made to the stock exchange announcements published by Navamedic ASA (the “Company“) on 23 June 2025 and 14 July 2025, regarding the contemplated partly underwritten rights issue to raise gross proceeds of between NOK 110 million and NOK 130 million (the “Rights Issue“) and the approval of the Rights Issue by the extraordinary general meeting of the Company.

The Financial Supervisory Authority of Norway (Nw. Finanstilsynet) has today, on 19 September 2025, approved a prospectus prepared by the Company in connection with the Rights Issue and the listing on the Oslo Stock Exchange of up to 6,046,511 offer shares in the Rights Issue and up to 272,090 new shares to be issued in connection with the settlement of the underwriting fee to the underwriters in the Rights Issue (the “Prospectus“). The Prospectus is prepared in accordance with the simplified disclosure regime for secondary issuances as set out in the EU Prospectus Regulation (Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 and ancillary regulation, as implemented under Norwegian law).

The subscription period for the Rights Issue will commence on 22 September 2025 at 09:00 hours (CEST) and expire on 6 October 2025 at 16:30 hours (CEST). The subscription rights in the Rights Issue will be tradable on the Oslo Stock Exchange under the ticker code “NAVAT” from 09:00 hours (CEST) on 22 September 2025 to 16:30 hours (CEST) on 30 September 2025.

Subject to applicable local securities laws, the Prospectus, including the subscription form for the Rights Issue, will be made available at the Company’s website www.navamedic.com (http://www.navamedic.com), as well as www.dnb.no/emisjoner (http://www.dnb.no/emisjoner) and www.nordea.com/en/issuances (http://www.nordea.com/en/issuances). Printed copies of the Prospectus may be obtained free of charge by contacting DNB Carnegie, a part of DNB Bank ASA (Tel: +47 91 50 48 00) or Nordea Corporate Finance, a part of Nordea Bank Abp, filial i Norge (Tel: +47 24 01 34 62).

The Company has retained DNB Carnegie, a part of DNB Bank ASA and Nordea Corporate Finance, a part of Nordea Bank Abp, filial i Norge as managers for the Rights Issue (the “Managers“). Advokatfirmaet Thommessen AS is engaged as Norwegian legal counsel for the Company in connection with the Rights Issue.

For more information, please contact:

Kathrine Elisabeth Gamborg Andreassen, CEO, Navamedic ASA

Tel: +47 951 78 880

Email: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic ASA

Tel: +47 917 62 842

Email: lars.hjarrand@navamedic.com

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

About Navamedic ASA

Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

– IMPORTANT INFORMATION –

This announcement does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States or any other jurisdiction. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to “qualified institutional buyers” as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States.

Any offering and listing of the securities referred to in this announcement will be made by means of the Prospectus. This announcement is an advertisement and is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the “Prospectus Regulation”). The approval of the Prospectus by the Financial Supervisory Authority of Norway (Nw. Finanstilsynet) should not be understood as an endorsement of the securities referred to in this announcement. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the Prospectus, to fully understand the potential risks and rewards associated with the decision to invest in the securities. Copies of the Prospectus will, following publication, be available from the Company’s registered office and, subject to certain exceptions, on the website of the Managers.

In any EEA Member State other than Norway, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as “Relevant Persons”). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

This document is not for publication or distribution in, directly or indirectly, the United States, Canada, Australia, the Hong Kong Special Administrative Region of the People’s Republic of China or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful, and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States or to publications with a general circulation in the United States of America.

The Managers are acting for the Company in connection with the Rights Issue and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Rights Issue or any transaction or arrangement referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. This announcement is made by and is the responsibility of, the Company. Neither the Managers nor any of their affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. Neither the Managers nor any of their respective affiliates accepts any liability arising from the use of this announcement.